Transenterix (TRXC) Stock Soars On Regulatory Submission

TransEnterix TRXC Stock News

Transenterix Inc (NYSEAMERICAN: TRXC) is up more than 40% in the market this morning after announcing that it has submitted a 510(k) application to the FDA. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

TRXC Stock Pops On Regulatory Submission

TransEnterix investors are jumping for joy this morning as the stock soars after a regulatory submission. In a press release, the company said that it has filed a 510(k) submission with the FDA.

The submission surrounds an Intelligent Surgical Unit known as (ISUTM)1 that was designed to enable machine vision capabilities on the Senhance Surgical System.

In the release, TRXC said that the initial features of the product are designed to increase control in visualization beyond what has previously been available. Working with the ey-tracking camera control feature that’s already part of the Senhance System, the ISU will respond to commands and recognize certain objects and locations in the surgical field.

Moreover, the company said that the hardware is designed to be compatible with future augmented intelligence features. Currently, TRXC is working to bring scene cognition and surgical image analytics to the table.

In a statement, Anthony Fernando, President and CEO at TransEnterix, had the following to offer:

TransEnterix is the first company to seek FDA clearance for machine vision technology in abdominal robotic surgery. Rather than simply passing a video signal to the surgeon, the Intelligent Surgical Unit for Senhance will initially have the ability to actually visualize the surgical field to guide movement and capture information. This technology advance is an important first step towards enabling augmented intelligence and we believe it will support continued machine vision driven advances in surgery performed with the Senhance Digital Laparoscopy Platform.

This Is Great News

At the end of the day, the news issued by TRXC is great for investors. The Senhance Surgical System is already at the top of its class, being called one of the most innovative surgical tools in its space.

With machine vision capabilities, more control will be provided to the surgeon during these procedures.

Not to mention, the fact that the company is currently working on more add ons and further technological capabilities, the Senhance System and the various technologies that can be added to it will likely stay at the top.

All in all, as TRXC continues to innovate, generating better outcomes in the operating room, the stock is likely to continue growing, generating strong profits for investors!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.